Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Erich Fisher, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by David Fisher and Keith Flaherty.
Connection Strength

3.888
  1. Author Correction: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2020 Dec; 20(12):757.
    View in: PubMed
    Score: 0.941
  2. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 Apr 05; 12(5):349-61.
    View in: PubMed
    Score: 0.516
  3. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res. 2011 Aug 01; 17(15):4922-8.
    View in: PubMed
    Score: 0.488
  4. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
    View in: PubMed
    Score: 0.239
  5. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN? pathways. Nat Rev Clin Oncol. 2019 09; 16(9):549-562.
    View in: PubMed
    Score: 0.216
  6. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692.
    View in: PubMed
    Score: 0.183
  7. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncol. 2015 Dec; 1(9):1340-1.
    View in: PubMed
    Score: 0.166
  8. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015 Dec; 15(12):747-56.
    View in: PubMed
    Score: 0.165
  9. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310.
    View in: PubMed
    Score: 0.165
  10. Pathways and therapeutic targets in melanoma. Oncotarget. 2014 Apr 15; 5(7):1701-52.
    View in: PubMed
    Score: 0.149
  11. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.140
  12. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
    View in: PubMed
    Score: 0.059
  13. Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nat Commun. 2019 11 14; 10(1):5157.
    View in: PubMed
    Score: 0.055
  14. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med. 2016 09; 22(9):1056-61.
    View in: PubMed
    Score: 0.044
  15. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16.
    View in: PubMed
    Score: 0.043
  16. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784.
    View in: PubMed
    Score: 0.042
  17. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
    View in: PubMed
    Score: 0.038
  18. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.037
  19. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
    View in: PubMed
    Score: 0.037
  20. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53.
    View in: PubMed
    Score: 0.037
  21. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013 Oct 01; 2(10):e26615.
    View in: PubMed
    Score: 0.036
  22. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.034
  23. A melanoma molecular disease model. PLoS One. 2011 Mar 30; 6(3):e18257.
    View in: PubMed
    Score: 0.030
  24. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 01; 70(13):5213-9.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.